On Tuesday, D Boral Capital initiated coverage on Tevogen Bio Holdings Inc. (NASDAQ:TVGN), a clinical-stage immunotherapy company. The company’s lead pipeline product, TVGN-489, is a SARS-CoV-2-specific therapy. Tevogen’s pipeline includes preclinical programs targeting Epstein-Barr…
Continue reading...